NetScientific PLC (LON:NSCI) said its portfolio company, Vortex BioSciences, has presented a study demonstrating how its technology can combine with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).
The healthcare IP commercialisation group said the study, presented at the NanoBiotech Montreux 2018 conference in Switzerland, introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells isolated from blood samples.
The researchers believed the results of the study provided feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.
Impedance spectroscopy involves applying a wave frequency to a system or surface and measuring the changes and is often used on various types of biological tissue.
Francois Martelet, chief executive of NetScientific and chairman of Vortex, said Vortex’s technology was “ready to be adopted by large pharmaceutical players” following the creation of an automated and reliable process and the signing of a manufacturing agreement with German firm STRATEC for its VTX-1 liquid biopsy platform in November.